NextCure, Inc. (NXTC) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
NXTC Revenue Growth
NXTC Revenue Analysis (2017–2025)
As of May 8, 2026, NextCure, Inc. (NXTC) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue.
Looking at the longer-term picture, NXTC's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $22.4 million in 2020.
When compared to Healthcare sector peers including FATE (-51.2% YoY), RCUS (+67.4% YoY), and AGEN (+10.4% YoY). Compare NXTC vs FATE →
NXTC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| NXTCCurrent | $0 | - | - | - | |
 FATE | $7M | -51.2% | -26.7% | -2222.4% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% |
NXTC Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-2,185,000 | - | $-57,616,000 | - |
| 2024 | $0 | - | $0 | - | $-59,748,000 | - |
| 2023 | $0 | - | $0 | - | $-67,637,000 | - |
| 2022 | $0 | - | $0 | - | $-75,909,000 | - |
| 2021 | $0 | -100.0% | $0 | - | $-70,765,000 | - |
| 2020 | $22.4M | +252.6% | $-24,176,000 | -108.0% | $-41,225,000 | -184.2% |
| 2019 | $6.3M | - | $-27,869,000 | -439.1% | $-37,482,000 | -590.5% |
| 2018 | $0 | - | $-1,677,000 | - | $-23,196,000 | - |
| 2017 | $0 | - | $-582,000 | - | $-15,549,000 | - |
See NXTC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NXTC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NXTC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNXTC — Frequently Asked Questions
Quick answers to the most common questions about buying NXTC stock.
Is NXTC's revenue growth accelerating or slowing?
NXTC TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is NXTC's long-term revenue growth rate?
NextCure, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is NXTC's revenue distributed by segment?
NXTC reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.